🟢 NUVB is trading 4.1% up today on oncology pipeline progress and trial advancements

NUVB is trading 4.1% up at $6.00, extending a multi-day rally driven by positive clinical and regulatory progress across its oncology pipeline.

• The move follows recent strength tied to the advancement of IBTROZI and safusidenib trials and regulatory filings.
• Shares are outperforming a weak broader market as the company continues to attract interest following upbeat revenue and positive analyst commentary.